Virulence blockers as alternatives to antibiotics: type III secretion inhibitors against Gram-negative bacteria.
about
The resveratrol tetramer (-)-hopeaphenol inhibits type III secretion in the gram-negative pathogens Yersinia pseudotuberculosis and Pseudomonas aeruginosaSmall-Molecule Inhibitors of the Type III Secretion SystemChemical inhibitors of the type three secretion system: disarming bacterial pathogensStructural Characterisation of Tpx from Yersinia pseudotuberculosis Reveals Insights into the Binding of Salicylidene Acylhydrazide CompoundsIsolation of Salmonella mutants resistant to the inhibitory effect of Salicylidene acylhydrazides on flagella-mediated motilityGlobal Analysis of Type Three Secretion System and Quorum Sensing Inhibition of Pseudomonas savastanoi by Polyphenols Extracts from Vegetable ResiduesMutations in hemG mediate resistance to salicylidene acylhydrazides, demonstrating a novel link between protoporphyrinogen oxidase (HemG) and Chlamydia trachomatis infectivity.Small-molecule type III secretion system inhibitors block assembly of the Shigella type III secreton.Discovery and characterization of inhibitors of Pseudomonas aeruginosa type III secretion.Identification of small-molecule inhibitors of Yersinia pestis Type III secretion system YscN ATPase.Candidate vaginal microbicides with activity against Chlamydia trachomatis and Neisseriagonorrhoeae.Derivatives of plant phenolic compound affect the type III secretion system of Pseudomonas aeruginosa via a GacS-GacA two-component signal transduction systemBenzylidene acylhydrazides inhibit chlamydial growth in a type III secretion- and iron chelation-independent manner.Type I signal peptidase and protein secretion in Staphylococcus epidermidis.An in vivo high-throughput screening approach targeting the type IV secretion system component VirB8 identified inhibitors of Brucella abortus 2308 proliferation.Discovery of plant phenolic compounds that act as type III secretion system inhibitors or inducers of the fire blight pathogen, Erwinia amylovora.The host-encoded Heme Regulated Inhibitor (HRI) facilitates virulence-associated activities of bacterial pathogens.Small-molecule inhibitors suppress the expression of both type III secretion and amylovoran biosynthesis genes in Erwinia amylovora.Cis-2-dodecenoic acid signal modulates virulence of Pseudomonas aeruginosa through interference with quorum sensing systems and T3SSThe Chlamydial Type III Secretion Mechanism: Revealing Cracks in a Tough Nut.Synthesis and structure-activity relationships of novel phenoxyacetamide inhibitors of the Pseudomonas aeruginosa type III secretion system (T3SS).Application of β-lactamase reporter fusions as an indicator of effector protein secretion during infections with the obligate intracellular pathogen Chlamydia trachomatisType III Secretion-Dependent Sensitivity of Escherichia coli O157 to Specific KetolidesPre-clinical pharmacokinetics and anti-chlamydial activity of salicylidene acylhydrazide inhibitors of bacterial type III secretionObacunone represses Salmonella pathogenicity islands 1 and 2 in an envZ-dependent fashionRole for the chlamydial type III secretion apparatus in host cytokine expression.Design and characterization of a polyamine derivative inhibiting the expression of type III secretion system in Pseudomonas aeruginosaAn NF-κB-based high-throughput screen identifies piericidins as inhibitors of the Yersinia pseudotuberculosis type III secretion system.Productive steps toward an antimicrobial targeting virulence.Uncivil engineers: Chlamydia, Salmonella and Shigella alter cytoskeleton architecture to invade epithelial cells.A small-molecule compound belonging to a class of 2,4-disubstituted 1,3,4-thiadiazine-5-ones suppresses Salmonella infection in vivo.Chlamydial biology and its associated virulence blockers.Ecology and evolution as targets: the need for novel eco-evo drugs and strategies to fight antibiotic resistance.Surface organelles assembled by secretion systems of Gram-negative bacteria: diversity in structure and function.Targeting the type III secretion system to treat bacterial infections.Approaches targeting the type III secretion system to treat or prevent bacterial infections.Designing drugs that overcome antibacterial resistance: where do we stand and what should we do?Identification of bacterial target proteins for the salicylidene acylhydrazide class of virulence-blocking compounds.Novel compounds targeting the enterohemorrhagic Escherichia coli type three secretion system reveal insights into mechanisms of secretion inhibition.Anti-virulence Strategies to Target Bacterial Infections.
P2860
Q21132404-62F7F11D-429A-49DA-A97A-E95BF097D409Q26781403-5CCCC02B-6F71-4035-94FD-794D6606CF9EQ27013353-2AFDA3F5-6BE4-4275-A6C3-EFEF04868A24Q27677661-4003FAAE-D37C-474E-86B9-8B8EF9808978Q28484814-A7343676-929B-4066-9515-6E7EEA375747Q28554351-479E397A-A35C-4AB5-8BE0-527836439422Q30449313-ADA08A40-6A05-4BA3-B638-9702156B6AC0Q30853039-57508473-1800-4D58-9479-CF6C8D2E3D9AQ33533545-6D27B50D-C33B-4B80-9A4B-1D0948DBA356Q33911034-2A2AAE8F-7C5E-4E2F-BD40-0DCDB32BA7C1Q33987702-3E255A68-D0D9-44C2-8E53-738B0F6A621AQ34039055-ABDDAAF8-E600-404B-B028-58AC8970E62DQ34056674-3657EAC0-39CE-4B27-AD11-6012A6777999Q34484327-272A633A-8D97-4499-949F-61C0B4DB7829Q34739706-E117FA83-BECD-419A-AC99-590410E3680CQ34774479-2EE7DD1A-F5AA-4826-A963-6B48038ABD93Q34850929-B48BBFCC-7104-4E82-B379-969E12CC78A7Q34893460-6012DBA8-A948-4A62-85E3-FF6A5300BC3CQ35019815-439DD221-8173-409E-A24F-C014832A513BQ35075114-E9A5B63A-C9C3-4102-B3D3-428C930FE03AQ35118409-C72B8A2E-EDFC-4E45-B87A-97434B60CAEAQ35741537-500EFF79-1E83-4E1C-9D63-D8A99F044009Q35829561-80B1273C-DD99-4E8B-BEEC-FC601EF6ECE1Q36192395-5C8AA176-FD47-4043-A617-5C54F5BC6FB8Q36277143-A6A2C2D0-7B81-40FB-9CE3-11323EE9ABEAQ37032989-E267993E-7D72-49B5-9715-31DEEFDC8572Q37147855-E3830C98-ADBD-44B8-8DB0-7EE95FC04E8CQ37544635-2E84F673-AB40-45B1-B321-1DF62E338EBFQ37561914-A93A5D50-95C2-4408-8720-B2DE59101F16Q37781063-914CAC92-69EF-4CB4-AC39-C5EE4340ABC2Q37838071-2FF202F0-F3C4-46C7-B2D1-4919DE053171Q37847713-91462A08-474B-425F-8E36-D21427DFCC21Q37876027-79BB03F5-360A-4E8B-AEFB-D3A613FBAE2DQ38006509-6D403406-D31A-47B8-8561-FEF41E1DFF33Q38167861-4219DD25-8BE7-48FF-BC55-1C86E208C745Q38366322-74609EC8-9D35-4DE2-892B-BC673CEFB90AQ38485480-5EBCF06D-38DF-4B8A-B367-1D62A77882F3Q38676435-6D581CAB-5E9C-4E22-AA08-F6CE94B190D2Q38756953-90FD4725-F6CE-4732-B585-EE99446692EEQ38760476-3A3D36D6-EEA3-408E-A901-75D2E061B19D
P2860
Virulence blockers as alternatives to antibiotics: type III secretion inhibitors against Gram-negative bacteria.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Virulence blockers as alternat ...... gainst Gram-negative bacteria.
@en
Virulence blockers as alternat ...... gainst Gram-negative bacteria.
@nl
type
label
Virulence blockers as alternat ...... gainst Gram-negative bacteria.
@en
Virulence blockers as alternat ...... gainst Gram-negative bacteria.
@nl
prefLabel
Virulence blockers as alternat ...... gainst Gram-negative bacteria.
@en
Virulence blockers as alternat ...... gainst Gram-negative bacteria.
@nl
P2093
P2860
P1476
Virulence blockers as alternat ...... gainst Gram-negative bacteria.
@en
P2093
P2860
P356
10.1111/J.1365-2796.2008.01941.X
P407
P577
2008-04-03T00:00:00Z